GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

Styliani Karanika, Theodoros Karantanos, Shinji Kurosaka, Jianxiang Wang, Takahiro Hirayama, Guang Yang, Sanghee Park, Alexei A. Golstov, Ryuta Tanimoto, Likun Li, Timothy C. Thompson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the mechanisms of docetaxel activity whereas ERK1/2-c-Myc-CXCR4 signaling is implicated in the development of resistance and induction of migration. The aim of this study was to evaluate the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic potential in prostate cancer (PCa) cells. Methods: The synergistic effects of the docetaxel and GLIPR1-ΔTM were evaluated with DNA fragmentation, DAPI staining and MTS using paired t-test and isobologram study. The effects of the drugs on JNK and ERK1/2-c-Myc-CXCR4 signaling were evaluated with Western blot, DNA fragmentation, and MTS assays using the JNK inhibitor SP600125, and CXCR4 siRNA. The results of docetaxel and GLIPR1-ΔTM combination on migration were examined with scratch assay using the CXCR4 inhibitor AMD3100 while our hypothesis was examined in vivo using VCaP orthotopic xenograft model. Results: We found that GLIPR1-ΔTM synergized with docetaxel to induce apoptosis in VCaP and PC-3 PCa cells through induction of JNK signaling and concomitant inhibition of ERK1/2-c-Myc-CXCR4 signaling. We showed that JNK activation mediates the apoptotic effects of the drug combination and that CXCR4 knockdown increases its efficacy. We also found that the addition of GLIPR1-ΔTM to docetaxel decreases the migration of VCaP and PC-3 cells. The combination treatment with docetaxel and GLIPR1-ΔTM inhibited tumor growth and decreased metastatic potential in VCaP xenografts more than single agents did. Conclusions: Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.

Original languageEnglish
Article number122
JournalMolecular Cancer
Volume14
Issue number1
DOIs
Publication statusPublished - Jun 19 2015
Externally publishedYes

Fingerprint

docetaxel
Prostatic Neoplasms
Cell Death
Castration
DNA Fragmentation
Heterografts
Apoptosis

Keywords

  • c-Myc
  • Combination treatment
  • CXCR4
  • Docetaxel
  • ERK1/2
  • GLIPR1-ΔTM
  • JNK
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Cite this

Karanika, S., Karantanos, T., Kurosaka, S., Wang, J., Hirayama, T., Yang, G., ... Thompson, T. C. (2015). GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. Molecular Cancer, 14(1), [122]. https://doi.org/10.1186/s12943-015-0395-0

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. / Karanika, Styliani; Karantanos, Theodoros; Kurosaka, Shinji; Wang, Jianxiang; Hirayama, Takahiro; Yang, Guang; Park, Sanghee; Golstov, Alexei A.; Tanimoto, Ryuta; Li, Likun; Thompson, Timothy C.

In: Molecular Cancer, Vol. 14, No. 1, 122, 19.06.2015.

Research output: Contribution to journalArticle

Karanika, S, Karantanos, T, Kurosaka, S, Wang, J, Hirayama, T, Yang, G, Park, S, Golstov, AA, Tanimoto, R, Li, L & Thompson, TC 2015, 'GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells', Molecular Cancer, vol. 14, no. 1, 122. https://doi.org/10.1186/s12943-015-0395-0
Karanika, Styliani ; Karantanos, Theodoros ; Kurosaka, Shinji ; Wang, Jianxiang ; Hirayama, Takahiro ; Yang, Guang ; Park, Sanghee ; Golstov, Alexei A. ; Tanimoto, Ryuta ; Li, Likun ; Thompson, Timothy C. / GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. In: Molecular Cancer. 2015 ; Vol. 14, No. 1.
@article{8bd122d67d0b423e8fddf6e6963e7bc6,
title = "GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells",
abstract = "Background: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the mechanisms of docetaxel activity whereas ERK1/2-c-Myc-CXCR4 signaling is implicated in the development of resistance and induction of migration. The aim of this study was to evaluate the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic potential in prostate cancer (PCa) cells. Methods: The synergistic effects of the docetaxel and GLIPR1-ΔTM were evaluated with DNA fragmentation, DAPI staining and MTS using paired t-test and isobologram study. The effects of the drugs on JNK and ERK1/2-c-Myc-CXCR4 signaling were evaluated with Western blot, DNA fragmentation, and MTS assays using the JNK inhibitor SP600125, and CXCR4 siRNA. The results of docetaxel and GLIPR1-ΔTM combination on migration were examined with scratch assay using the CXCR4 inhibitor AMD3100 while our hypothesis was examined in vivo using VCaP orthotopic xenograft model. Results: We found that GLIPR1-ΔTM synergized with docetaxel to induce apoptosis in VCaP and PC-3 PCa cells through induction of JNK signaling and concomitant inhibition of ERK1/2-c-Myc-CXCR4 signaling. We showed that JNK activation mediates the apoptotic effects of the drug combination and that CXCR4 knockdown increases its efficacy. We also found that the addition of GLIPR1-ΔTM to docetaxel decreases the migration of VCaP and PC-3 cells. The combination treatment with docetaxel and GLIPR1-ΔTM inhibited tumor growth and decreased metastatic potential in VCaP xenografts more than single agents did. Conclusions: Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.",
keywords = "c-Myc, Combination treatment, CXCR4, Docetaxel, ERK1/2, GLIPR1-ΔTM, JNK, Prostate cancer",
author = "Styliani Karanika and Theodoros Karantanos and Shinji Kurosaka and Jianxiang Wang and Takahiro Hirayama and Guang Yang and Sanghee Park and Golstov, {Alexei A.} and Ryuta Tanimoto and Likun Li and Thompson, {Timothy C.}",
year = "2015",
month = "6",
day = "19",
doi = "10.1186/s12943-015-0395-0",
language = "English",
volume = "14",
journal = "Molecular Cancer",
issn = "1476-4598",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

AU - Karanika, Styliani

AU - Karantanos, Theodoros

AU - Kurosaka, Shinji

AU - Wang, Jianxiang

AU - Hirayama, Takahiro

AU - Yang, Guang

AU - Park, Sanghee

AU - Golstov, Alexei A.

AU - Tanimoto, Ryuta

AU - Li, Likun

AU - Thompson, Timothy C.

PY - 2015/6/19

Y1 - 2015/6/19

N2 - Background: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the mechanisms of docetaxel activity whereas ERK1/2-c-Myc-CXCR4 signaling is implicated in the development of resistance and induction of migration. The aim of this study was to evaluate the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic potential in prostate cancer (PCa) cells. Methods: The synergistic effects of the docetaxel and GLIPR1-ΔTM were evaluated with DNA fragmentation, DAPI staining and MTS using paired t-test and isobologram study. The effects of the drugs on JNK and ERK1/2-c-Myc-CXCR4 signaling were evaluated with Western blot, DNA fragmentation, and MTS assays using the JNK inhibitor SP600125, and CXCR4 siRNA. The results of docetaxel and GLIPR1-ΔTM combination on migration were examined with scratch assay using the CXCR4 inhibitor AMD3100 while our hypothesis was examined in vivo using VCaP orthotopic xenograft model. Results: We found that GLIPR1-ΔTM synergized with docetaxel to induce apoptosis in VCaP and PC-3 PCa cells through induction of JNK signaling and concomitant inhibition of ERK1/2-c-Myc-CXCR4 signaling. We showed that JNK activation mediates the apoptotic effects of the drug combination and that CXCR4 knockdown increases its efficacy. We also found that the addition of GLIPR1-ΔTM to docetaxel decreases the migration of VCaP and PC-3 cells. The combination treatment with docetaxel and GLIPR1-ΔTM inhibited tumor growth and decreased metastatic potential in VCaP xenografts more than single agents did. Conclusions: Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.

AB - Background: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the mechanisms of docetaxel activity whereas ERK1/2-c-Myc-CXCR4 signaling is implicated in the development of resistance and induction of migration. The aim of this study was to evaluate the hypothesis that the combination treatment with docetaxel and GLIPR1-ΔTM will synergistically induce greater cell death and inhibit the emergence of resistance and development of metastatic potential in prostate cancer (PCa) cells. Methods: The synergistic effects of the docetaxel and GLIPR1-ΔTM were evaluated with DNA fragmentation, DAPI staining and MTS using paired t-test and isobologram study. The effects of the drugs on JNK and ERK1/2-c-Myc-CXCR4 signaling were evaluated with Western blot, DNA fragmentation, and MTS assays using the JNK inhibitor SP600125, and CXCR4 siRNA. The results of docetaxel and GLIPR1-ΔTM combination on migration were examined with scratch assay using the CXCR4 inhibitor AMD3100 while our hypothesis was examined in vivo using VCaP orthotopic xenograft model. Results: We found that GLIPR1-ΔTM synergized with docetaxel to induce apoptosis in VCaP and PC-3 PCa cells through induction of JNK signaling and concomitant inhibition of ERK1/2-c-Myc-CXCR4 signaling. We showed that JNK activation mediates the apoptotic effects of the drug combination and that CXCR4 knockdown increases its efficacy. We also found that the addition of GLIPR1-ΔTM to docetaxel decreases the migration of VCaP and PC-3 cells. The combination treatment with docetaxel and GLIPR1-ΔTM inhibited tumor growth and decreased metastatic potential in VCaP xenografts more than single agents did. Conclusions: Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.

KW - c-Myc

KW - Combination treatment

KW - CXCR4

KW - Docetaxel

KW - ERK1/2

KW - GLIPR1-ΔTM

KW - JNK

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84934279636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934279636&partnerID=8YFLogxK

U2 - 10.1186/s12943-015-0395-0

DO - 10.1186/s12943-015-0395-0

M3 - Article

VL - 14

JO - Molecular Cancer

JF - Molecular Cancer

SN - 1476-4598

IS - 1

M1 - 122

ER -